A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
By J. Neoptolemos, D. Stocken, H. Friess, C. Bassi, J. Dunn, H. Hickey, H. Beger, L. Fernández‐Cruz, C. Dervenis, F. Lacaine and 6 more. New England Journal of Medicine, 2004
2,607 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/27f67f8915a8281c1f9f4a7c3feb4ba4e17e270c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- EMT and dissemination precede pancreatic tumor formation (2012, result): “Tumors contain both E-cad+ and E-cad cells (I) as well as Zeb1+ and Zeb1 cells (H), providing direct evidence for MET. metastatic disease within 5 years (Neoptolemos et al., 2004), a finding that is consistent with early spread.”
- Tumor-stroma interactions in pancreatic ductal adenocarcinoma (2007, neutral): “The treatment modality of adjuvant radiation or chemoradiation is inferior to chemotherapy in a randomized clinical trial for the treatment of PDA (29), implying that added radiation may”
- Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. (2014, neutral): “adjuvant treatment in pancreas cancer [166].”
- 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience (2006, neutral): “There have been two large phase III trials for adjuvant therapy following resection for pancreatic cancer that have been reported within the past 10 years.(45,46) Both trials were performed in Europe and were generally interpreted by the European community as providing weak evidence that chemotherap”
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (2023, background): “The recent demonstration of benefit from chemotherapy in the adjuvant setting suggests that studies of erlotinib after surgery for localized disease may also be warranted.(36,37) This trial provides proof of principle of targeting HER1/EGFR in pancreatic cancer and shows erlotinib can improve surviv”
- Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy (2015, neutral): “Adjuvant (post-operative) chemotherapy can improve outcome despite the modest anti-tumor efficacy of these agents (Neoptolemos et al , 2004; Stocken et al , 2005).”